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A Comparison of Error Rates Between Intravenous Push
Methods: A Prospective, Multisite, Observational Study
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Objectives: Current literature estimates the error rate associated with
the preparation and administration of all intravenous (IV) medications to be
9.4% to 97.7% worldwide. This study aims to compare the number of observed
medication preparation and administration errors between the only commercially
available ready-to-administer product (Simplist) and IV push traditional practice,
including a cartridge-based syringe system (Carpuject) and vials and syringes.
Methods: A prospective, multisite, observational study was conducted in
3 health systems in various states within the United States between
December 2015 and March 2016 to observe IV push medication prepara-
tion and administration. Researchers observed a ready-to-administer prod-
uct and IV push traditional practice using a validated observational method
and a modified data collection sheet. All observations were reconciled to
the original medication order to determine if any errors occurred.
Results: Researchers collected 329 observations (ready to adminis-
ter = 102; traditional practice = 227) and observed 260 errors (ready to ad-
minister = 25; traditional practice = 235). The overall observed error rate
for ready-to-administer products was 2.5%, and the observed error rate
for IV push traditional practice was 10.4%.
Conclusions: The ready-to-administer group demonstrated a statistically
significant lower observed error rate, suggesting that use of this product is
associated with fewer observed preparation and administration errors in the
clinical setting. Future studies should be completed to determine the poten-
tial for patient harm associated with these errors and improve clinical prac-
tice because it relates to the safe administration of IV push medications.
Key Words: IV push medication administration, direct observation,
medication errors, safety, error rates, ready-to-administer IV
push medication, nurse administration
(J Patient Saf 2018;14: 60–65)
T he use of intravenous (IV) medications is essential to provid-ing patient care in the hospital setting. An estimated 44% of
nurses administer injectable medications more than 5 times per
shift.1 However, these products carry a high potential for patient
harm because of the number of complex manipulations required
to administer, compatibility concerns, narrow therapeutic indexes,
and challenges with reversing pharmacologic effects of drugs ad-
ministered by this route.2 This risk is recognized by the medical
community, and 99%of nurses agree that errors related to IVmed-
ication use pose a serious risk to patients.1 In addition, many IV
medications were identified as having a serious risk for patient
harm on the high-alert medication list for acute care settings.3
A study in 2012 by Lahue et al4 estimated that 1.2 million hos-
pitalizations each year are impacted by preventable adverse drug
events associated with injectable medications. Almost half (48%)
of the errors that occur with all IV medications happen during
preparation or administration,1 but error rates related to these prac-
tices vary significantly in the literature. Studies worldwide estimate
the error rate with all IV medications to be between 9.4% and
97.7%,with IV push administrations demonstrating higher error rates
than IV infusions.5–12 Common IVmedication errors included failure
to maintain aseptic technique during drug preparation, use of the
wrong diluent, and incorrect labeling of an IV product.5–12
One of the factors associated with an increased potential for
error with IV medications is the number of complex manipula-
tions required when preparing and administering these drugs.2,13
Drug manufacturers have begun to develop and market ready-to-
administer IV push products with the aim of reducing this com-
plexity of drug preparation and administration, while minimizing
the potential for errors and patient harm. Ready-to-administer
products are viewed as the IV drug delivery systems of choice,
particularly because of their low risk for contamination and ease
of use.14,15 They are recommended for use in procedural areas
and for dispensing anesthetic products to help reduce errors while
maintaining efficiency.15–18 Although there is support for the use
of these products, the authors could not identify any literature
quantifying error rates between the available IV push methods in
actual practice. One study using a simulated method did find a re-
duction in medication errors when using ready-to-administer
products; however, the authors of the simulation study note poten-
tial limitations when applied to the clinical setting, suggesting that
further research needs to be conducted to validate their findings.19
The primary objective of this study was to compare the number
of observed medication preparation and administration errors
between the only commercially available ready-to-administer
product (Simplist; Fresenius Kabi, Lake Zurich, Ill)20 and IV
push traditional practice, including a cartridge-based syringe
system (Carpuject; Hospira, Lake Forest, Ill)21 and vials and syrin-
ges. Secondary objectives included further analysis of the observed
error rate and identifying specific types of errors observed within
each group of the study. The researchers hypothesized that use
of a ready-to-administer product would result in fewer observed
medication errors because of the reduced complexity of manipula-
tions required to administer the product as intended.
METHODS
A prospective, multisite, observational study of IV push medi-
cation preparation and administration was conducted in 3 health
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systems in various states within the United States between
December 2015 and March 2016. This study was approved by
both the Purdue University Institutional Review Board (IRB)
and through each study site's own specific review process. In-
formed consent was obtained from all nursing personnel before
participation in the study.
The following inclusion criteria were used to select study site
candidates: use of the only commercially available ready-to-
administer product (Simplist), accreditation by The Joint Commis-
sion, Magnet designation from the American Nurses Credentialing
Center, and a Hospital Safety Score (generated by The Leapfrog
Group) of C or greater. These inclusion criteria were used as
objective measures to identify sites with robust safety cultures.
Sites were excluded if they were pediatric units or had previously
used the AU MEDS (MedAccuracy, LLC, Auburn University,
Auburn, Ala) system. The AU MEDS system is a validated
observational method designed to collect data through direct ob-
servation at the point of medication preparation and administra-
tion.22 Excluding sites with previous AU MEDS use helped
ensure consistency in staff response to observers, AUMEDS pro-
cesses, and relative observation methods. Each site was contacted
by a study team member and completed a letter of interest articu-
lating their desire to participate in the study. After review, all sites
accepted the Purdue University IRB approval and 1 site obtained
additional approval from a site-specific IRB.
This observational research included 2 study groups to assess
differences in observed errors and error rates associated with
ready-to-administer products compared with traditional practice.
The first group consisted of observations of medication pre-
paration and administration of a ready-to-administer product
(Simplist). The second group consisted of observations of medica-
tion preparation and administration of IV push traditional practice,
FIGURE 1. Opportunities for error by IV push method.
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including a cartridge-based syringe system (Carpuject) and vial
and syringe. It was estimated that 240 observations of both ready-
to-administer and IV push traditional practice (with approximately
120 per technique) would sufficiently power the study (β at 0.8)
to detect a difference of 15% in observed errors in medication
preparation and administration between the 2 study groups.
Observations were collected using AU MEDS, and all re-
searchers successfully completed the AUMEDS training program
and exam. Researchers who participated in the data collection also
completed shared observations at a separate site not included in
the study, and the percentage agreement on each observation
was used to calculate a Cohen κ interrater reliability score.
Researchers directly observed medication preparation and ad-
ministration at 3 separate study sites. Nurses were observed after re-
moval of the IV push medication from the automated dispensing
cabinets (ADCs) to administration of the dose to the patient. Obser-
vation typically occurred between 8 AM and 6 PM to capture asmany
doses as possible, based on ADC dispensing data. Only patient care
areas that were serviced by ADCs were included in this study.
Before on-site observations, researchers defined the steps
required in a correct IV push medication preparation and ad-
ministration process for each IV push method by completing
3 distinct failure modes and effects analyses (FMEAs) for each
observed method. An FMEA, or a step-wise approach used to
identify all of the possible ways a process may fail, was developed
for the Simplist, vial and syringe, and Carpuject process by break-
ing down all steps perceived necessary for successful administra-
tion of medication using information from manufacturer package
inserts and best practice guidelines. These steps were objectively
discussed and debated by the research team, and each FMEA
was adapted to create an observational research form, which was
used to collect relevant data at each study site. Both study groups
included IV push methods that had 10 steps (Fig. 1) or opportu-
nities for error based on this impartial, objective analysis (the
Carpuject method required 13 steps, however all but 1 Carpuject
vial used without the Carpuject cartridge. Therefore, those obser-
vations were coded as a 10-step vial and syringe administration).
Data regarding completion of each of the technique steps
along with the following information were collected: date of prep-
aration and administration, unit, hospital, observer, patient code,
time when medication was removed from the ADC, administra-
tion time, medication given, and comments. All observations were
reconciled to the original medication order and the predefined
process steps to determine if an error occurred.
Definition of Error and Error Rate
For this study, an error was defined as a deviation of the ob-
served medication preparation and administration from the previ-
ously defined steps or any deviation from the original medication
order. The overall observed error rate was defined as the total
number of technique errors divided by the total number of oppor-
tunities for error.
Definition of Dilution and Dilution Error
Dilution was defined as any IV push medication that was di-
luted with normal saline or other diluent before administration
to the patient. Dilution did not include reconstituting powdered
medication with the appropriate diluent (e.g., pantoprazole). Dilu-
tion errors were defined as dilution occurring when no dilution
was indicated. Dilution errors also included no dilution occurring
when dilution was indicated in site-specific policy or the medica-
tion administration record.
Statistics
The average number of errors per administration was calcu-
lated by study group, both overall and within each study site.
The chance of committing any errors per observation was com-
pared between the 2 study groups using the Fisher exact test. Sta-
tistically significant differences were defined as P < 0.05. The
number of errors per observation (with a total number of opportu-
nities for errors being 10 for each group or 13 for the 1 observed
Carpuject administration) was compared between the 2 techniques
using a stratified log-linear model, using the 3 sites as strata.
Cohen κ as an index of interrater agreement between 2 raters
on categorical data was calculated for each pair of the 3 raters. The
desired interrater reliability was defined as a Cohen κ coefficient
of greater than 0.8.
RESULTS
To determine the observed error rate for IV push medication
preparation and administration of the ready-to-administer prod-
ucts and IV push traditional practice, researchers directly observed
this process at 3 separate sites for a total of 337 hours. Researchers
collected a total of 329 observations (ready to administer = 102;
traditional practice = 227) and observed a total of 260 errors
(ready to administer = 25; traditional practice = 235). The Cohen
κ calculated for interrater agreement was greater than or equal to
0.867 for each researcher pair (Table 1).
Ready-to-administer products were associated with fewer
observed errors than IV push traditional practice. Only 22 of
102 ready-to-administer (22%) observations contained errors
versus 179 of 227 traditional practice (79%) observations
contained errors (P < 0.001).
Observed error rates were calculated using total number of
errors divided by total number of opportunities for error. To
control for potential site differences, a stratified log-linear analysis
with site as strata was performed. This analysis confirmed a uni-
formly significant lower observed error rate for ready-to-administer
products at each site (P < 0.02), allowing the data to be pooled
for an aggregate analysis. Overall, site B demonstrated a lower
observed error rate for both ready-to-administer and traditional
practice than site A or C; however, the error rate for ready to
TABLE 1. Interrater Agreement as Measured by Cohen κ
Rater Pairs Cohen κ
Observer A and B 0.93
Observer A and C 0.93
Observer B and C 0.87
TABLE 2. Average of Number of Errors per Opportunity by Site
and Group
Site Group Error Rate P
All sites Ready to administer 0.025 <0.02
All sites Traditional practice 0.104
Site A Ready to administer 0.020 0.01
Site A Traditional practice 0.126
Site B Ready to administer 0.004 0.02
Site B Traditional practice 0.044
Site C Ready to administer 0.034 <0.001
Site C Traditional practice 0.105
P values are for group comparisons within site, based on a stratified
model with site as strata.
Hertig et al J Patient Saf • Volume 14, Number 1, March 2018
62 www.journalpatientsafety.com © 2017 Wolters Kluwer Health, Inc. All rights reserved.
administer was still significantly lower than traditional prac-
tice (P = 0.018) (Table 2). The overall observed error
rate for ready to administer was 2.5% (25 errors and 1020
opportunities for error), and the observed error rate for IV push
traditional practice was 10.4% (235 errors and 2270 oppor-
tunities for error) (Fig. 2).
Therewere a total of 21 labeling errors (ready to administer = 3;
traditional practice = 18), 85 dilution errors (ready to adminis-
ter = 21; traditional practice = 64), and 153 disinfection errors
(ready to administer = 0; traditional practice = 153). Medications
diluted more than 50% of the time during the observations included
diphenhydramine, famotidine, hydromorphone, hydralazine, ketorolac,
labetalol, lorazepam, metoclopramide, and promethazine. Spe-
cific dilution observed error totals are noted in Table 3.
A total of 65 IV push medication administrations with a
Carpuject vial were observed during the study. The Carpuject vial
was used with a Carpuject cartridge and administered as directed
by the package insert during 1 observation and was used and
recorded as a vial and syringe administration during the other
64 observations.
DISCUSSION
Ready-to-administer products were developed with the goal of
reducing the complexity of IV push medication administration
and improving safe medication use practices of injectable prod-
ucts.23 The primary objective of this research was to compare
the number of observed medication preparation and administra-
tion errors between the only commercially available ready-to-
administer product and IV push traditional practice. The results
demonstrate that there is a statistically significant difference be-
tween ready-to-administer and IV push traditional practice, with
fewer errors associated with preparation and administration of
ready-to-administer products.
Risk Points and Primary Objective
Counting the number of steps in the ready-to-administer pro-
cess and comparing that absolute number against the number of
steps required to administer a medication via vial and syringe
may not accurately represent the risk of a given process. For exam-
ple, a step in the Simplist process requires the user to “push
plunger rod to break stopper loose.” This step arguably carries less
risk of harm to the patient when compared with select steps in the
vial and syringe process including “select and attach appropriate
needle” or “disinfect rubber entry field.” In reviewing each process
step for the study groups, the relative risk points and likelihood of
patient harm should be assessed against total number of steps.15
In addition, the study results suggest that these points of higher risk
found in the traditional practice group of the study were also asso-
ciated with higher rates of errors. The lower observed error rate at
site B may be attributed to the smaller overall number of obser-
vations collected there compared with sites A and C.
Secondary Objectives
Secondary objectives for this research included further analysis
of the specific types of errors observed within each study group
including extra dose, omission, unordered medication, wrong
FIGURE 2. Error rate per opportunity, overall and by site.
TABLE 3. Total Number of Dilutions and Dilution Errors
by Drug
Drug
Dilution Error
(% of Total)
Dilution
(% of Total)
Total
Observations
Ondansetron 19 (32) 25 (42) 59
Hydromorphone 18 (21) 65 (76) 86
Diphenhydramine 16 (50) 18 (56) 32
Ketorolac 9 (50) 9 (50) 18
Famotidine 6 (86) 6 (86) 7
Promethazine 6 (32) 17 (89) 19
Morphine 4 (7) 29 (48) 61
Metoclopramide 2 (50) 2 (50) 4
Lorazepam 1 (33) 2 (67) 3
Methylprednisolone 1 (13) 2 (25) 8
Hydralazine 1 (100) 1 (100) 1
Labetalol 1 (100) 1 (100) 1
Furosemide 1 (10) 4 (40) 10
Pantoprazole 0 3 (27) 11
Chlorothiazide 0 0 (0) 2
Metoprolol 0 0 (0) 2
Thiamine 0 0 (0) 2
Dexamethasone 0 0 (0) 1
Prednisolone 0 0 (0) 1
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dose, wrong form, wrong route, wrong time, and wrong tech-
nique. Errors associated with disinfection, dilution, and labeling
were included as a wrong technique error.
There were 3 labeling errors with ready-to-administer products
compared with 18 errors with IV push traditional practice. These
results suggest that using vial and syringe practice requires addi-
tional manipulation, which can result in leaving an unlabeled sy-
ringe unattended. Previous studies suggest that unlabeled
medications can be given by mistake because of confusion about
syringe contents and potentially result in patient harm.2,15 The
findings in the current study regarding the lack of syringe labeling
are similar to findings in a study that observed nursing practice in
a simulated environment.19 The ready-to-administer products in
this study are labeled by the manufacturer eliminating the need
for this step before medication administration. The 3 errors ob-
served as part of this study occurred because nursing staff with-
drew the medication from the Simplist syringe and then injected
the medication into an unlabeled flush syringe, which was left un-
labeled and unattended. The Joint Commission's National Patient
Safety Goals outline best practices with labeling medications, in-
dicating that all medications, medication containers, and other so-
lutions on and off the sterile field in perioperative and other
procedural settings should be labeled.24 There have been cases
of serious harm reported when patients were accidentally admi-
nistered flush syringes that included medication but were left
unattended and unlabeled.16 The Institute for Safe Medication
Practices released a “Medication Safety Alert” outlining the
risks associated with unlabeled IV medications and also pro-
vided a best practices document to help organizations minimize
risks associated with improperly labeled products.16
Disinfecting and sterilizing all potential points of contamina-
tion are key factors in preventing nosocomial infections. Preven-
tion of these types of infections is a priority for hospitals and
healthcare systems, and various state and federal organizations
have included infection-related metrics into quality programs.25
A risk point identified in this study was the disinfection of the vial
stopper before puncture and withdrawal of the medication in
the traditional practice research group. Best practice suggests the
rubber stopper of medication vials is disinfected with sterile
70% alcohol before the insertion of a needle to protect against
the transfer of microorganisms from the healthcare provider
or environment to the patient.25 The study results demonstrated
106 errors resulting from failure to disinfect the vial stopper in
the traditional practice group, whereas no errors were observed
in the ready-to-administer group because this product required
no additional disinfecting before administration to the patient.
This difference is clinically significant, given the safety risks asso-
ciated with contaminated medications.
The unnecessary dilution of medications, particularly ready-to-
administer products, continues to be a topic of debate among
those involved in best practice development. In many care set-
tings, there seems to be a practice disposition toward dilution,
rather than determining a specific need for dilution on a drug-
by-drug or case-by-case basis.26 The United States Pharmacopeia
Chapter <797>, a standard for compounded sterile preparations,
indicates that any transfer of medication from 1 device to another
presents a potential contamination and safety risk.27 Health pro-
fessionals should seek to minimize these transfers, attempting to
complete the successful administration of a medication in the
fewest steps necessary. Researchers observed a total of 47 ready-
to-administer and 137 traditional practice dilutions throughout
the duration of this study. Per study definitions, 21 ready-to-
administer dilutions and 64 traditional practice dilutions were
deemed to be errors. Although both study groups demonstrated a
clinically significant number of dilutions, the ready-to-administer
product was associated with fewer of these types of errors. There
are a variety of safety issues associated with dilution including an
increased likelihood of unlabeled and mislabeled syringes, the
possibility of contamination, the potential for dosing errors, and
an increased likelihood for precipitate formation with the use of
an incompatible diluent.2,15 Best practices advise that IV push
medications should only be diluted when recommended by the
manufacturer, supported by evidence in peer-reviewed biomedical
literature, or in accordance with institutional guidelines.15 The
package inserts for Simplist products do not instruct healthcare
professionals to dilute before administration, with the exception
of doses that exceed what is commercially available in the pre-
packaged syringes.20 Specifically, the manufacturer recommends
not to “introduce any other fluid into the syringe at any time.”
Study researchers found differences in site-specific guidance doc-
uments when completing preparatory research because institu-
tional policies are not uniform in nature. Researchers also found
dilution suggestions within such places as the medication admin-
istration record or built within the physician order sets. Coordina-
tion between nursing, pharmacy, and medicine departments is
encouraged to ensure that dilution only occurs when necessary
for optimal patient care.
Other Errors Observed
The inclusion of the cartridge-based syringe system (Carpuject)
into this study resulted in 65 observed uses of Carpuject across the
3 sites. There was only a single observation of a Carpuject being
used as intended with the Carpuject cartridge equating to a 1.5%
success rate with this process. In 64 cases, the Carpuject was
misused by neglecting to attach the necessary cartridge, resulting
in the device being used as a vial. To ensure accurate study docu-
mentation, as soon as a Carpuject was used as a vial, the study ob-
server assessed the remaining administration procedure using the
vial process observation tool. This ensured a consistent approach
to error detection by assuming that a Carpuject used as a vial could
still serve utility. Despite the small number of cartridge-based sy-
ringe system observations, the low observed success rate would
seem to indicate that there is a need for additional education and
training on these devices if they are to be used in a manner consis-
tent with manufacturer guidelines.
Remaining Gaps and Further Research
This research study was designed to assess the use of ready-to-
administer products when compared with traditional practice,
with a specific focus on technique errors. The results from these
primary and secondarymeasures have provided insights not previ-
ously reported in the literature. The information learned has sub-
sequently highlighted additional gaps in available knowledge
that were outside the scope of this study.
Further research is needed to assess the true impact of harm
resulting from the errors identified in this study. An outcomes
study linking the risks of each process step with resulting patient
harm from the errors would help further demonstrate the impact
on patient safety. Additional gaps in IV push administration center
around the decision to dilute medications, and there is a need for
research and education regarding appropriate dilution practices.
Further research should identify key stakeholders, including front-
line healthcare professionals, medication safety experts, and clin-
ical leaders to determine appropriate guidelines for effective and
safe dilution. In addition, further exploration into the relative
safety of ready-to-administer products as related to infection-control
considerations is warranted. This study demonstrated a clinically
significant difference in appropriate disinfection when the ready-
to-administer products group was compared with traditional practice.
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Determining the risk and patient impact of inappropriate disinfec-
tion, accompanied by evidenced-based recommendations, would
assist hospitals and health systems in their journey toward achiev-
ing a comprehensive culture of cleanliness.
Limitations
Statistical analysis confirmed that the 3 sites were similar
enough to pool for data analysis; however, no study site is exactly
the same and there may be potential differences in the culture, pro-
cesses, and people who were involved in administering IV push
medications. Moreover, variability in individual site policies and
procedures surrounding dilution practices determined whether a
dilution was categorized as an error or an appropriate dilution.
Changes in these policies or procedures would impact the final er-
ror calculations. Observations were also collected sequentially as
opposed to randomly, which may have affected the observed error
rate. Finally, the number of steps chosen to be observed in each
group was developed from an FMEA analysis and any change
in the number of these process steps has the potential to alter the
final calculated error rates.
CONCLUSIONS
Intravenous push medication preparation and administration
of ready-to-administer products and traditional practice, includ-
ing a cartridge-based syringe system and vial and syringes, were
observed in a prospective, multisite, observational study. The
ready-to-administer group had an observed error rate of 2.5%,
whereas the traditional practice group had an observed error rate
of 10.4%. This difference was found to be statistically significant
and would suggest that use of ready-to-administer products is as-
sociated with fewer observed errors in the study's clinical settings.
This study addressed key questions while identifying additional
gaps in the available literature surrounding IV push medication
practice. Future studies should be completed to determine the po-
tential for patient harm associated with these errors and improve
clinical practice because it relates to the safe administration of
IV push medications.
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